Atai Life Sciences N.V.

DB:9VC Stock Report

Market Cap: €198.3m

Atai Life Sciences Management

Management criteria checks 2/4

Atai Life Sciences' CEO is Srini Rao, appointed in Jun 2024, has a tenure of less than a year. total yearly compensation is $1.73M, comprised of 31.7% salary and 68.3% bonuses, including company stock and options. directly owns 0.07% of the company’s shares, worth €138.10K. The average tenure of the management team and the board of directors is 1.2 years and 3.9 years respectively.

Key information

Srini Rao

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage31.7%
CEO tenureless than a year
CEO ownership0.07%
Management average tenure1.2yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Srini Rao's remuneration changed compared to Atai Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$129m

Jun 30 2024n/an/a

-US$58m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$2mUS$550k

-US$40m

Sep 30 2023n/an/a

-US$67m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$149m

Dec 31 2022US$4mUS$550k

-US$152m

Sep 30 2022n/an/a

-US$196m

Jun 30 2022n/an/a

-US$194m

Mar 31 2022n/an/a

-US$205m

Dec 31 2021US$12mUS$481k

-US$168m

Sep 30 2021n/an/a

-US$166m

Jun 30 2021n/an/a

-US$218m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$3mUS$400k

-US$170m

Compensation vs Market: Srini's total compensation ($USD1.73M) is above average for companies of similar size in the German market ($USD900.29K).

Compensation vs Earnings: Srini's compensation has been consistent with company performance over the past year.

CEO

Srini Rao (55 yo)

less than a year

Tenure

US$1,734,650

Compensation

Dr. Srinivas G. Rao, M.D., Ph D., also known as Srini, serves as Co-Chief Executive Officer of Atai Life Sciences N.V. since June 01, 2024. He serves as Clinical Advisory Board Member at Bionomics Limited...

Leadership Team

NamePositionTenureCompensationOwnership
Christian Angermayer
Founder & Chairman of the Supervisory Boardno dataUS$158.96k2.48%
€ 4.9m
Srinivas Rao
Co-Founder & Co-CEOless than a yearUS$1.73m0.070%
€ 138.1k
Florian Brand
Co-Founder6.5yrsUS$3.03m0.20%
€ 391.2k
Anne Johnson
Chief Financial Officer1.2yrsUS$1.17m0.044%
€ 87.0k
Michael Raven
Senior Vice President of Operations1.2yrsno datano data
Frank Stegert
Vice President of Investment & Venture Management3.9yrsno datano data
Ryan Barrett
Senior VP3.9yrsno datano data
Glenn Short
Senior Vice President of Early Development1.2yrsno datano data
Sahil Kirpekar
Chief Business Officer2.1yrsno data0.038%
€ 75.9k
Kevin Craig
Senior Vice President of Clinical Development1.2yrsno datano data

1.2yrs

Average Tenure

43yo

Average Age

Experienced Management: 9VC's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Christian Angermayer
Founder & Chairman of the Supervisory Board3.9yrsUS$158.96k2.48%
€ 4.9m
Sabrina Johnson
Independent Member of Supervisory Board3.9yrsUS$151.96k0%
€ 0
Laurent Fischer
Independent Supervisory Directorless than a yearno datano data
Amir Kalali
Independent Member of Supervisory Board3.9yrsUS$140.46k0.0028%
€ 5.5k
Scott Braunstein
Independent Supervisory Directorless than a yearno datano data
Andrea Smiley
Independent Member of Supervisory Board3.9yrsUS$150.46k0.0028%
€ 5.5k
Michael B. Auerbach
Independent Lead Member of Supervisory Board3.9yrsUS$158.96k0.31%
€ 619.6k

3.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 9VC's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 19:43
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Sumant Satchidanand KulkarniCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.